<html><body><h2>Case: 1440115</h2><h3> CDS Time: 1982-07-11</h3>
<patient name=1440115>
82.0 year old Asian_or_Pacific-Islander_Non-Hispanic Female
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">82</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">8</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">88</td><td width="200">1982-3-10</td></tr>
<tr><td width="200">Phosphorus</td><td width="200">4</td><td width="200">1982-5-31</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">74</td><td width="200">1982-5-31</td></tr>
<tr><td width="200">Chloride</td><td width="200">100.0</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">50</td><td width="200">1982-5-31</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">60</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">BNP</td><td width="200">11,191</td><td width="200">1982-3-9</td></tr>
<tr><td width="200">Weight</td><td width="200">108</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">HbA1C</td><td width="200">7</td><td width="200">1982-5-31</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">117</td><td width="200">1982-5-31</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">147</td><td width="200">1982-5-31</td></tr>
<tr><td width="200">SGOT</td><td width="200">17</td><td width="200">1982-3-10</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">120</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">0</td><td width="200">1982-3-10</td></tr>
<tr><td width="200">Height</td><td width="200">60</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">Potassium</td><td width="200">4</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">147</td><td width="200">1982-5-31</td></tr>
<tr><td width="200">BUN</td><td width="200">25</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">HCT</td><td width="200">41</td><td width="200">1982-3-13</td></tr>
<tr><td width="200">HGB</td><td width="200">14</td><td width="200">1982-3-13</td></tr>
<tr><td width="200">Sodium</td><td width="200">137</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">Albumen</td><td width="200">4</td><td width="200">1982-5-31</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.1</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">7</td><td width="200">1982-5-31</td></tr>
<tr><td width="200">Pulse</td><td width="200">83</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">PLT</td><td width="200">180</td><td width="200">1982-3-13</td></tr>
<tr><td width="200">WBC</td><td width="200">5</td><td width="200">1982-3-13</td></tr>
<tr><td width="200">eGFR</td><td width="200">51</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1982-7-11</td></tr>
<tr><td width="200">SGPT</td><td width="200">31</td><td width="200">1982-3-10</td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200"></td><td width="200">1982-7-11</td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1982-7-11</td></tr>
<tr><td width="200">Heart_Failure</td><td width="200"></td><td width="200">1982-7-11</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1982-3-13</td></tr>
<tr><td width="200">Osteoporosis</td><td width="200"></td><td width="200">1982-3-9</td></tr>
<tr><td width="200">Myocardial_Infarction</td><td width="200"></td><td width="200">1982-3-12</td></tr>
<tr><td width="200">Sex</td><td width="200">Female</td><td width="200"></td></tr>
<tr><td width="200">Race</td><td width="200">Asian_or_Pacific-Islander_Non-Hispanic</td><td width="200"></td></tr>
</table>
<p><b>Medications:</b> glyburide(10.0) aspirin(81.0) metformin(2000.0) atorvastatin(20.0) valsartan(160.0) carvedilol(12.5) furosemide(0.0) Insulin(0.04) glipizide(5.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of myocardial infarction]()</td></tr>
<tr><td width="200">DM (2ary prev)  BP controlled</td>
<td width="200"></td>
<td width="200"> Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(120/null) && presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Heart Failure  (Secondary Prev) BP controlled</td>
<td width="200"></td>
<td width="200"> Heart Failure (Secondary Prevention)[Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(120/null) && presence of heart failure]()</td></tr>
<tr><td width="200">MI (secondary prevention) BP controlled</td>
<td width="200"></td>
<td width="200"> Myocardial Infarction (Secondary Prevention)[Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(120/null) && presence of myocardial infarction]()</td></tr>
<tr><td width="200">Heart Failure (second prev) BP cont</td>
<td width="200"></td>
<td width="200"> Heart Failure (Secondary prevention)[Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(120/null) && heart failure present]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Sex(Female) && Age(82.0/1970-1-1)]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(51.0/1982-7-11)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(51.0/1982-7-11)]()</td></tr>
<tr><td width="200">On meds & Presence of strong contraindication to HCTZ or using bad drug partner</td>
<td width="200"></td>
<td width="200"> Hypertension[taking furosemide && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">active prescription for furosemide</td>
<td width="200"></td>
<td width="200"> active prescription for furosemide[taking furosemide]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(82.0/1970-1-1)]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Hypertension with MI and K>=3.5</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.5/1982-7-11) && presence of MI]()</td></tr>
<tr><td width="200">Absence of Stage D HF</td>
<td width="200"></td>
<td width="200"> Absence of Stage D HF[Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF)]()</td></tr>
<tr><td width="200">Osteoporosis</td>
<td width="200">1982-03-09</td>
<td width="200"> Osteoporosis()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1982-03-12</td>
<td width="200"> Myocardial_Infarction()</td></tr>
<tr> <td width="200"></td>
<td width="200">1982-07-11</td>
<td width="200"> Heart_Failure()</td></tr>
<tr> <td width="200"></td>
<td width="200">1982-07-11</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1982-03-13</td>
<td width="200"> Hypertension()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.5/1982-7-11) && presence of MI]()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1982-07-11</td>
<td width="200"> DM-Type2()</td></tr>
<tr><td width="200">Hypertension_Defined</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.5/1982-7-11) && presence of MI]()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
</patient>
<h1 align="center">ATHENA Heart Failure Guideline</h1>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF))</i>]
</ul>
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> achieved(LDL_Cholesterol(74.0/1982-5-31))
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(120/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Class II a</b>
<ul>
<li>Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)
</ul>
<li><b>Class I</b>
<ul>
<li>Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)
<li>Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
</ul>
<li><b>Class III</b>
<ul>
<li>Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage C HF</b><br>
<ul>
</ul>
<li><b> </b><br>
<ul>
<li><b>General Recommendations <font color=FF0000>preferred</font></b>(strict rule-in condition<i> HF ICD9 code OR( signs and structural abnormality)</i> evaluate to <b> true</b> because <i>Presence of HF</i>)])
Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)
Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)

<li><b>Referrals <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])
Class I
<li><b>Stage B HF action <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
</ul>
</ul>
<b>Considerations for adding drug: </b><ul><li>aldosterone antagonist<ul><li>preference: neutral<li>No comment</ul><li>hydralazine and nitrates<ul><li>preference: neutral<li>No comment</ul><li>Beta blocker for stage C heart failure(Carvedilol)<ul><li>Already being used<li>preference: ruled out</ul><li>Beta blocker Stage C with MI(Carvedilol)<ul><li>Already being used<li>preference: ruled out</ul></ul><b>Considerations for adding drug: </b><ul><li>Ace_Inhibitor(Captopril, Lisinopril, Enalapril)<ul><li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction) </font><li>rec add ace: dose adjustent based on kidney functio(Refer to specific ACE Inhibitor dose adjustments based on kidney function.)<li>monitoring renal function and K(Need to find content)<li>preference: preferred</ul><li>digoxin<ul><li>preference: neutral<li>No comment</ul><li>Beta Blocker Stage B no MI<ul><li>preference: neutral<li>No comment</ul><li>ARB<ul><li>Already being used<li>preference: ruled out</ul><li>Beta blocker stage B post MI(Carvedilol)<ul><li>Already being used<li>preference: ruled out</ul><li>NDHP CCB<ul><li>Contraindications:  Heart_Failure(Heart_Failure)  Myocardial_Infarction(Myocardial_Infarction) <li>preference: ruled out</ul></ul></body></html>